1,326 publications from this institution
The effects of plasminogen activator inhibitor-1 (PAI-1) gene inactivation on hemostasis, thrombosis and thrombolysis were studied in homozygous PAI-1-deficient (PAI-1-/-) mice, generated by homologous recombination in D3 embryonic stem cells. Diluted (10-fold) whole blood clots from PAI-1-/- and from PAI-1 wild type (PAI-1+/+) mice underwent limited but significantly different (P < 0.001) spontaneous lysis within 3 h (6 +/- 1 vs 3 +/- 1%, respectively). A 25-microliters 125I-fibrin-labeled normal murine plasma clot, injected into a jugular vein, was lysed for 47 +/- 5, 66 +/- 3, and 87 +/- 7% within 8 h in PAI-1+/+, heterozygous PAI-1-deficient (PAI-1+/-), and PAI-1-/- mice, respectively (P = 0.002 for PAI-1+/+ vs PAI-1-/- mice). Corresponding values after pretreatment with 0.5 mg/kg endotoxin in PAI-1+/+ and PAI-1-/- mice, were 35 +/- 5 and 91 +/- 3% within 4 h, respectively (P < 0.001). 11 out of 26 PAI-1+/+ but only 1 out of 25 PAI-1-/- mice developed venous thrombosis (P = 0.004) within 6 d after injection of 10 or 50 micrograms endotoxin in the footpad. Spontaneous bleeding or delayed rebleeding could not be documented in PAI-1-/- mice after partial amputation of the tail or of the caecum. Thus, disruption of the PAI-1 gene in mice appears to induce a mild hyperfibrinolytic state and a greater resistance to venous thrombosis but not to impair hemostasis.
hile the war against acute coronavirus disease 2019 (COVID-19) is still raging, reports of a long-lasting post-COVID-19 syndrome are surging."Long COVID" progressed from a mere oddity to an acknowledged public health issue worldwide.A formal definition of post-acute COVID-19 syndrome (ie, long COVID) is evolving, and for the purposes of this review, we consider it as persistent symptoms or complications lasting more than 30 days after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.Symptoms of long COVID involve multiple organs and include shortness of breath, fatigue, chest pain, loss of taste and/or smell, and cognitive dysfunction.Studies investigating the incidence of long COVID report broad heterogeneity (likely attributable to variations in study cohorts and long COVID definition/symptoms), and its manifestation may range from ≈30% to a staggering ≥80% of all SARS-CoV-2infected patients. 1,2Although there is hope that vaccination may reduce the risk of developing long COVID, studies remain inconclusive thus far.Breakthrough infections frequently occur in vaccinated people and may unfortunately still cause an escalation in long COVID cases.Detection and treatment of long COVID is challenging because the molecular underpinnings of the condition remain largely unknown.